Search Results - Qingbo Liu

Co-Treatment With Resveratrol and FGF1 Protects Against Acute Liver Toxicity After Doxorubicin Treatment via the AMPK/NRF2 Pathway by Xianchou Xu, Xianchou Xu, Qingbo Liu, Jiahao Li, Mengjie Xiao, Ting Gao, Xiaohui Zhang, Guangping Lu, Jie Wang, Yuanfang Guo, Peinan Wen, Junlian Gu

Connect to this object online.

Resveratrol Attenuates High Glucose-Induced Osteoblast Dysfunction via AKT/GSK3β/FYN-Mediated NRF2 Activation by Yue Xuan, Jie Wang, Xiaohui Zhang, Jie Wang, Jiahao Li, Qingbo Liu, Guangping Lu, Mengjie Xiao, Ting Gao, Yuanfang Guo, Cong Cao, Ou Chen, Kunli Wang, Yufeng Tang, Junlian Gu

Connect to this object online.

A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention by Young D. Kwon, Mangaiarkarasi Asokan, Jason Gorman, Baoshan Zhang, Qingbo Liu, Mark K. Louder, Bob C. Lin, Krisha McKee, Amarendra Pegu, Raffaello Verardi, Eun Sung Yang, VRC Production Program, Kevin Carlton, Nicole A. Doria-Rose, Paolo Lusso, John R. Mascola, Peter D. Kwong

Connect to this object online.

Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain by Young D. Kwon, Amarendra Pegu, Eun Sung Yang, Baoshan Zhang, Michael F. Bender, Mangaiarkarasi Asokan, Qingbo Liu, Krisha McKee, Bob C. Lin, Tracy Liu, Mark K. Louder, Reda Rawi, Mateo Reveiz, Andrew J. Schaub, Chen-Hsiang Shen, Nicole A. Doria-Rose, Paolo Lusso, John R. Mascola, Peter D. Kwong

Connect to this object online.